c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1

Cancer Research

Volumn 67, Issue 1, 2007, Pages 178-185

  Nielsen, Christina ^a   Thastrup, Jacob ^a   Bøttzauw, Trine ^a   Jäättelä, Marja ^a   Kallunki, Tuula ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Institute of Biology   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 9; PROTEIN E6; PROTEIN P19; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL IMMORTALIZATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTYPE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL STRAIN 3T3; CELL TRANSFORMATION; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NUDE MOUSE; ONCOGENE RAS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FEMALE; GENES, RAS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 9; NIH 3T3 CELLS; PHOSPHORYLATION; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSDUCTION, GENETIC;

EID: 33846446722     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2801     Document Type: Article

References (48)

1. Kallunki T, Su B, Tsigelny I, et al. JNK2 contains a specificity- determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 1994;8:2996-3007.
2. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15:2760-70.
3. Sanchez I, Hughes RT, Mayer BJ, et al. Hole of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994;372:794-8.
4. Minden A, Karin M. Regulation and function of the JNK subgroup of MAp kinases. Biochim Biophys Acta 1997;1333:F85-104.
5. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev 2002;12:14-21.
6. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
7. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005;1756:127-44.
8. Finco TS, Westwick JK, Norris JI, Beg AA, Der CJ, Baldwin AS, Jr. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997; 272:24113-6.
9. Pruitt K, Pruitt WM, Bilter GK, Westwick JK, Der CJ. Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. J Biol Chem 2002;277:31808-17.
10. Roberts TM. Cell biology. A signal chain of events. Nature 1992;360:534-5.
11. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89:457-67.
12. Eferl R, Wagner EF. AP-1; a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
13. Binetruy B, Smeal T, Karin M. Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature 1991;351:122-7.
14. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 1996;16:4504-11.
15. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 1991;354:494-6.
16. Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000;19:2657-63.
17. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. Suppression of Ras-stimulaled transformation by the JNK signal transduction pathway. Genes Dev 2003;17:629-37.
18. Sabapathy K, Hu Y, Kallunki T, et al. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol 1999;9:116-25.
19. Sabapathy K, Kallunki T, David JP, Graef I, Karin M, Wagner EF. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J Exp Med 2001;193:317-28.
20. Dietrich N, Thastrup J, Holmberg C, et al. JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways. Cell Death Differ 2004; 11:301-13.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
22. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-4.
23. Jacobsen K, Groth A, Willumsen BM. Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation. Oncogene 2002;21:3058-67.
24. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 2004;15:713-25.
25. Mechta F, Lallemand D, Pfarr CM, Yaniv M. Transformation by ras modifies AP1 composition and activity. Oncogene 1997;14:837-47.
26. Simons PJ, Dourmashkin RR, Turano A, Phillips DE, Chesterman FC. Morphological transformation of mouse embryo cells in vitro by murine sarcoma virus (Harvey). Nature 1967;214:897-8.
27. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
28. Cavender JF, Conn A, Epler M, Lacko H, Tevethia MJ. Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. J Virol 1995;69:923-34.
29. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.
30. Khosravi-Far R, White MA, Westwick JK, et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 1996; 16:3923-33.
31. Chen N, Nomura M, She QB, et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001;61:3908-12.
32. She QB, Chen N, Bode AM, Flavell RA, Dong Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 2002;62:1343-8.
33. Kemp CJ. Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol 2005;15:460-73.
34. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 1999;22:667-76.
35. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev 1999;89:115-24.
36. Potapova O, Gorospe M, Bost F, et al. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 2000;275:24767-75.
37. Yang YM, Bost F, Charbono W, et al. c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003;9:391-401.
38. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 1999;19:1938-49.
39. Antonyak MA, Kenyon LC, Godwin AK, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002;21:5038-46.
40. Tsuiki H, Tnani M, Okamoto I, et al. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 2003;63:250-5.
41. Kim HL, Vander Griend DJ, Yang X, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 2001;61:2833-7.
42. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339-42.
43. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002;62:6717-23.
44. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-57.
45. Tang Y, Chen Z, Ambrose D, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997;17:4454-64.
46. Albanese C, Johnson J, Watanabe G, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97.
47. Yu Q, Ciemerych MA, Sicinski P. Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins. Oncogene 2005;24:7114-9.
48. Zou X, Ray D, Aziyu A, et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 2002;16:2923-34.